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Background.  Epidemiological evidence for the encounter-level association between 
sexualised drug use and unprotected anal intercourse (UAI) in men who have sex with 
men (MSM) is unclear and has not examined MSM in England.  To estimate this 
association, we compared dyadic sexual encounters within respondents. 
Methods.  We used encounter-level data from a longitudinal online survey of MSM 
living in England and multilevel models to test univariate and multivariate associations 
between any respondent or partner drug use, specific respondent drug use, additional 
situational characteristics and UAI. 
Results.  Based on 6,742 encounters from 2,142 MSM, respondent drug use, and 
respondent use of certain specific drugs, were associated with increased UAI odds.  In 
univariate models, partner drug use was associated with increased UAI odds, but in 
multivariate models, only non-specific knowledge of partner drug use was associated 
with the same.  Encounters with non-regular-and-steady partners or that were not HIV 
seroconcordant were associated with decreased UAI risk. 
Discussion.  This is the first within-subjects comparison of drug use and UAI conducted 
on a sample from England, and the largest of its kind.  Findings are consistent with 
other studies, though associations between drug use and UAI are shaped by social 
contexts that may change over time. 
Keywords: epidemiology, high-risk behaviour, homosexual, sexual behaviour  
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Introduction 
 Epidemiologists and health promoters have sought to understand how situational 
characteristics specific to sexual encounters, including drug use, are associated with 
sexual risk behaviours.  Of the possible study designs for understanding these 
associations, designs that undertake ‘within-subjects’ comparisons of multiple sexual 
encounters are most informative, as they avoid confounding by person-level 
characteristics such as propensity towards risk-taking and sexual act preferences.1,2  
 Whether drug use and sexual risk behaviour are associated at the level of the 
sexual encounter remains unclear.  A systematic review of event-level analyses, 
including both single-event analyses and within-subjects comparisons, noted that 
evidence for associations between drug use and sexual risk behaviour is only well 
established for crystal methamphetamine and binge alcohol use.3  The evidence base 
from studies undertaking within-subjects comparisons to assess encounter-level 
associations between drug use and sexual risk behaviour among MSM4–15 is incomplete 
in several respects.  Studies may be out of date, as the most recent study in this field 
collected data before 2010.4  These studies have often drawn on small samples, as all 
but one5 enrolled fewer than 1,000 respondents.  These studies have also often 
considered drug use as a ‘composite’ variable covering a wide variety of different 
drugs,10–15 failing to acknowledge that specific drugs may be differentially associated 
with sexual risk behaviour.  Finally, these studies have also been limited to those 
conducted in the United States or Australia, and not other countries, such as the United 
Kingdom.16  Existing analyses of this association in the UK context are incomplete.  
While the ASTRA study17 was a landmark in developing UK-specific knowledge of the 
association between drug use and sexual risk behaviour, it relied on a clinic-based 
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sample to estimate cross-sectional, global associations between drug use histories and 
sexual risk behaviour histories.  Additional analyses on the dataset used in the current 
paper have focused on multipartner encounters18 and on respondent drug use in dyadic 
(i.e., between two partners) new partner encounters19.  Neither of these analyses was 
conducted using within-subjects comparisons, and previous work on dyadic encounters 
was unable to consider partner drug use and drew on a discrete survey module.  Patterns 
of sexual behaviour and drug use among MSM are likely to be shaped by social and 
cultural context, so evidence from one setting may not be readily generalizable to 
others. 
 Using data from the Sigma Panel, a longitudinal survey conducted in 2011-2012 
of MSM living in England, we report within-subjects comparisons testing associations 
between drug use and unprotected anal intercourse.  To our knowledge, this is the 
largest study of its kind both in terms of numbers of respondents and encounters 
analysed, and the first conducted in the United Kingdom. 
Methods 
 Participants were MSM living in England aged 16 years and above.  In five 
monthly waves of online data collection (sent 1st March 2011, 1st June 2011, 1st August 
2011, 1st November 2011 and 1st February 2012), participants were asked about their 
most recent sexual encounter with another man. 
 To avoid confounding or effect modification by the number of partners per 
encounter, we restricted this analysis to dyadic encounters.  We compared encounters in 
which unprotected anal intercourse (UAI) was reported against all other sexual 
encounters as the dependent variable in all models.  In this analysis, we included all 
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MSM who completed at least one of these monthly waves with information about a 
dyadic encounter. 
 Detailed survey methods are published elsewhere.20  In short, MSM were 
recruited via online dating websites, completion of a previous survey and email 
bulletins, and participants completed all surveys online.  The survey was approved by 
the London School of Hygiene and Tropical Medicine ethics committee (approval 
number 5834).  This analysis was approved by the Department of Social Policy and 
Intervention research ethics committee at the University of Oxford. 
 Drug use measures.  Participants were asked about both their use of poppers 
before sex and their use of alcohol or other drugs before sex separately using binary 
items.  If participants reported using alcohol or other drugs before sex, they were 
prompted to select from a list of 13 specific drugs (alcohol / Viagra®, Cialis®, 
Levitra® or other drugs that help to keep an erection / cannabis / ecstasy (E, XTC, 
MDMA) / amphetamine (speed) / crystal methamphetamine (crystal, meth, Tina) / 
heroin / mephedrone (4-MMC, meow, methylone, bubbles) / GHB, GBL (liquid 
ecstasy) / ketamine / LSD / cocaine / crack cocaine) plus a free-text option for ‘any 
other drug’. 
 Participants were also asked about their partners’ use of alcohol or other drugs.  
They were able to choose one of four responses: ‘Yes, and I know which drugs he 
used’, which was labelled ‘knowledge of specific drug use’, ‘Yes, but I don’t know 
which drugs he used’, which was labelled ‘non-specific knowledge of drug use’, ‘I 
don’t know if he used drugs’, which was labelled ‘unclear drug use’, and ‘No, he did 
not use drugs’.  If they chose the first option, they were prompted to select from the 
same list of 13 specific drugs or to specify ‘any other drug’. 
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 Covariates.  Covariates included several situational characteristics shown to be 
significantly associated with UAI in within-subjects comparisons in MSM: location of 
sex,5,11,13,21 partner relationship,12,15 and knowledge of partner HIV 
seroconcordance.12,22  First, we classified encounters by location of sex into: private 
(home or hotel), sex-on-premises venue (gay sex party, backroom, sex club, porn 
cinema, bathhouse or sauna) or cruising location (park, public toilet or other outdoors 
location).  Second, we classified partner relationship into: regular and steady 
(characterised by frequent contact, including boyfriend or husband), regular and non-
steady (repeat casual sex partner known to respondent, but not a primary sex partner) or 
one-off (one-night stand, paid sex or partner met for anonymous sex via the internet).  
Third, we classified encounters into those where the participant believed he and his 
partner to be: HIV seroconcordant (both partners either HIV positive or HIV negative); 
HIV serodiscordant (one partner HIV positive, the other HIV negative) or unknown 
HIV match (either the participant did not know his partner’s HIV status, or the 
participant did not believe his partner knew the participant’s HIV status, or both).  
Finally, we included the month of reporting in multivariate models to check reactivity 
arising from multiple measurements. 
 Analytic strategy.  We used random intercept models with encounters nested 
within participants and a Bernoulli distribution on the dependent variable.  Models were 
estimated using maximum likelihood in Stata 13.  We first estimated a null model with 
just the dependent variable, UAI, to estimate intra-cluster correlation.  We then entered 
any participant drug use, participant specific drug use, any partner drug use, partner 
specific drug use, and each covariate into separate ‘initial’ models.  We entered 
variables for specific drug use as a block both because use of specific drugs was not 
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exclusive of use of other specific drugs, and to isolate better any associations between 
specific drugs and UAI in light of the frequency of poly-drug combinations.  Due to 
model stability, we only included specific drugs reported in more than 1% of encounters 
(thus excluding amphetamine (speed), heroin, mephedrone, LSD and crack cocaine). 
 We then constructed two multivariate models: one with any participant drug use, 
any partner drug use, and the full set of covariates; and one with participant specific 
drug use and the full set of covariates.  We did not include partner specific drug use in 
the second multivariate model because of model instability due to the less prevalent 
reporting of partners’ use of specific drugs.  Missing data were handled by pairwise 
deletion because missingness was lower than 5% in all models. 
Results 
 We included 6,742 encounters from 2,142 MSM.  Each wave of data collection 
contributed roughly equally to the final set of encounters: 22.7% (1,528) of included 
encounters were reported in the first wave of data collection, 20.3% (1,369) in the 
second, 19.2% (1,293) in the third, 18.6% (1,253) in the fourth, and 19.3% (1,299) in 
the fifth.  Almost half of the sample reported possessing a university degree, 82% were 
White British, and respondents were on average 42.5 years of age (SD=11.9) (see table 
1).  On average, participants contributed 3.1 encounters (SD=1.5) to the analytic 
sample, of which 30.9% involved UAI.  A null model revealed an intra-cluster 
correlation of 66.8% with statistically significant variance at both the participant and 
encounter levels. 
 Initial models.  Compared with encounters featuring no substance use, 
encounters in which the participant reported substance use on his part had significantly 
greater odds of UAI (OR 2.02, 95% CI [1.67, 2.45]; see table 2). 
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 Encounters in which the participant had either specific or non-specific 
knowledge of his partner’s drug use were associated with similarly increased odds of 
UAI compared to encounters with no partner’s drug use.  However, only those 
encounters in which the participant had knowledge of specific drug use rose to 
statistical significance (OR 1.61, 95% CI [1.29, 1.99]).  Encounters in which the 
participant reported unclear partner drug use were associated with significantly 
decreased odds of UAI compared to encounters with no partner drug use (0.68, [0.49, 
0.97]). 
 Reported use of specific drugs by the participant or partner was associated with 
increased odds of UAI, with the exception of alcohol use by participant and ketamine 
use by the partner, but neither finding was statistically significant.  For both participants 
and partners in separate models, reported use of each of erectile dysfunction 
medications, crystal methamphetamine and GHB was significantly associated with 
increased odds of UAI.  Participant use of poppers was additionally associated with 
increased odds of UAI (this question was not asked about partners).  Partner use of 
cannabis was significantly associated with increased odds of UAI when controlling for 
other specific partner drug use, though not for participant use of cannabis. 
 Compared within participants to encounters in private locations, encounters in 
sex-on-premises venues and cruising locations were both associated with decreased 
odds of UAI.  Encounters with partners that were not regular and steady were similarly 
associated with decreased odds of UAI.  Finally, encounters with partners that were 
HIV serodiscordant or of unknown HIV status match were associated with decreased 
odds of UAI. 
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 Multivariate models.  Associations between any participant drug use and UAI 
and between participant specific drug use and UAI in multivariate models including 
covariates were similar to those in our initial models (see table 3).  However, the pattern 
of results for partner overall drug use changed when this variable was included in a 
model with additional covariates.  Specifically, associations between knowledge of 
specific partner drug use and increased UAI and between unclear partner drug use and 
decreased UAI in initial models did not remain significant in multivariate models.  Non-
specific knowledge of partner drug use was, however, significantly associated with 
increased odds of UAI (OR 1.63, 95% CI [1.01, 2.61]).  Examination of the correlation 
matrix for included variables showed that unclear partner drug use was correlated with 
unknown serostatus match (r=0.23), non-private location of sex (sex-on-premises 
venues r=0.32 and cruising locations r=0.15) and one-off partners (r=0.26).  Knowledge 
of specific partner drug use was also highly correlated with participant drug use 
(r=0.54). 
 Associations between encounters in sex-on-premises venues and less UAI were 
no longer significant in multivariate models, and the magnitude of the association 
between encounters in cruising or outdoors locations and UAI was decreased from 
initial models.  The magnitude of associations between relationship status with partner 
and UAI and between perceived partner HIV seroconcordance and UAI were somewhat 
attenuated in multivariate models, with the exception of encounters with serodiscordant 
partners, which were similar in associations with lower odds of UAI across all models. 
Discussion 
 This study presents the first evidence from England of within-subjects 
associations between drug use and UAI in MSM.  Participant drug use, both generally 
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and for some specific drugs, was associated with higher odds of UAI.  This association 
did not appear to be confounded by other key situational characteristics that have 
previously been shown to be significantly associated with UAI.  The shift in 
associations between univariate and multivariate models for partner drug use may 
reflect how perceptions of partner drug use, rather than the fact of partner drug use, may 
be confounded by other key situational characteristics.  This is especially likely given 
that unclear partner drug use was associated with encounters in locations that may be 
characterised by little communication between sexual partners.23,24  The finding that 
non-specific knowledge of partner drug use is associated with greater UAI mirrors 
findings in other studies on associations between UAI and composite drug use variables 
on the part of participant10,13 and partner. 
 Specific drug use.  Findings from this study agree with prior evidence from a 
systematic review3 and specific studies4,5,7 about associations between crystal 
methamphetamine and UAI.  Moreover, significant associations between use of both 
crystal methamphetamine and GHB and increased odds of UAI are especially important 
given their prominent use in ‘chemsex’ (the strategic combining of sex with drug use to 
enhance sexual performance and sensation) in MSM living in the United Kingdom25 
and other Western countries.26  Furthermore, our findings that use of poppers and 
erectile dysfunction medications are each associated with increased odds of UAI add 
important epidemiological evidence to analyses that have either been at the partnership 
level27 rather than at the level of the sexual encounter, or that have been qualitative in 
nature.28  Poppers and erectile dysfunction medications are reported to be used in the 
context of UAI to facilitate receptive and insertive anal intercourse, respectively, for 
longer encounters and with more successive partners in one sexual session than would 
 Within-subjects comparisons of sexualised drug use 11 
otherwise be feasible.25  Our finding that alcohol was not significantly associated with 
odds of UAI is in agreement with other within-subjects comparisons that have not found 
an effect,4,11 though other explanations include that associations between alcohol use 
and sexual risk are moderated by age,9,10 dependent on modality of UAI (i.e. receptive 
versus insertive UAI6), or dependent on the amount of alcohol consumed.5  We were 
unable to test these hypotheses in this study. 
 Covariates.  Though the covariates included in our models were not our primary 
focus in this paper, findings from these analyses merit comment.  Partner HIV 
serodiscordance and lack of familiarity are associated with decreased odds of UAI.  
Findings regarding location of sex and sexual risk behaviour add evidence to a specific 
area of investigation that, as a recent systematic review of within-subjects comparisons 
noted,29 requires additional research.  Though univariate models indicated that 
encounters in sex-on-premises venues and cruising locations are associated with 
decreased odds of UAI relative to encounters in private locations, findings on sex-on-
premises venues were not significant in multivariate models.  This is likely due to 
confounding by partner type and partner HIV seroconcordance. 
 Strengths and limitations.  Perhaps the most important strength of this study 
was the combination of sample size and attention to specific drugs used.  Our study’s 
large sample size in both participants and encounters provided improved power to 
examine specific drug use that was rare in the sample.  However, this study did not 
collect data using a diary format, so the maximum number of encounters per participant 
was five.  .  
 A strength and limitation of these analyses was restriction of the sample to 
dyadic encounters.  While this was useful in reducing confounding by the number of 
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partners per encounter, it does limit the generalisability of findings.  Multipartner sexual 
encounters may be markedly different from dyadic encounters in terms of 
communication about drug use and HIV serostatus.30 
 Our community-recruited sample consisted of more White British men and 
highly educated men than MSM in the UK at large.  Thus, findings may not be 
generalisable to the entire population of MSM living in England.  Community-recruited 
samples of MSM report higher risk than probability-based samples31 and recruitment 
source may influence results.32  To a degree, our within-subjects comparison attended to 
differences in baseline risk by participants, but this is not a perfect solution.  As with all 
retrospective recall surveys, our data may be subject to recall and reactivity bias.  
However, asking participants about their most recent encounter at multiple time points, 
rather than for multiple encounters at the same time, may have attenuated this.  We also 
controlled for wave of data collection. 
 Finally, a strength of our study is that, to our knowledge, our investigation 
contains the most recently collected data for testing within-subjects comparisons 
between drug use and sexual risk behaviour.  However, like the studies that came before 
it, findings may be specific to time and place as social, legal and supply contexts for 
drug use change. 
 Directions for future research.  Additional work should seek to better 
understand person-level moderation of encounter-level associations between drug use 
and sexual risk behaviour.9,10,15  New drug use trends will emerge as contexts change 
and as new compounds are synthesised.  For example, though patterns of sexualised 
drug use by MSM in the United States have long included crystal methamphetamine, 
this has only been recognised in the United Kingdom in the last several years.25  
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Moreover, when these data were collected, mephedrone use in MSM (which we were 
unable to analyse due to low frequency) was just emerging as a drug to be used in 
sexualised contexts.  Though we were underpowered in these analyses to investigate 
differences between receptive intercourse and insertive intercourse, future analyses 
should also seek to illuminate differences by coital positionality in associations between 
drug use and sexual risk.  Within-subjects comparisons of poly-drug combinations may 
also better approximate practices in sexualised drug use in MSM.  Finally, it is 
important to consider moderation of encounter-level relationships by person-level 
characteristics, such as ethnicity, that are associated with HIV prevalence or sexual risk. 
 Future research into interventions for sexual risk behaviour and sexualised drug 
use should seek to balance person-level behaviours with situational characteristics.  Our 
null model revealed that two-thirds of the variation in UAI across encounters was at the 
person-level, rather than due to differences between encounters.  However, our findings 
also revealed specific strong associations between drug use and sexual risk behaviour.  
Addressing situational use of GHB and crystal methamphetamine, as well as of poppers 
and erectile dysfunction medications, could present a useful focus.  This is especially 
given that many interventions for sexual risk reduction in drug-using MSM have 
focused on drug dependence rather than situational risk.33 
 Conclusion.  This study presents the first within-subjects comparison of drug 
use and sexual risk behaviour in MSM from a UK sample.  It offers current evidence of 
significant associations between UAI and both any drug use and specific drugs used, 
including drugs implicated in chemsex, and contributes to a field in which the question 
of associations between drug use and sexual risk behaviour continues to be discussed.  
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Table 1.  Characteristics of included participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
% (n) 
Mean (SD, range) 
Age (n=2,134) 42.5 (11.9, 17-78) 
16-19 1.3% (28) 
20-29 14.7% (313) 
30-39 24.2% (517) 
40-49 31.3% (668) 
50-59 19.5% (416) 
60-69 8.2% (174) 
70+ 0.8% (18) 
Education (n=2,129) 
 
Low (no secondary qual, CSE, O-level) 17.8% (379) 
Medium (A-level, higher ed below degree) 32.6% (694) 
High (university degree) 49.6% (1,056) 
Gross income per annum (n=2,132) 
 
<£5,000 5.2% (111) 
£5,000-£9,999 8.1% (173) 
£10,000-£14,999 8.7% (185) 
£15,000-£19,999 11.5% (245) 
£20,000-£24,999 11.5% (246) 
£25,000-£29,999 9.9% (211) 
£30,000-£34,999 9.9% (211) 
£35,000-£39,999 6.1% (129) 
≥£40,000 22.6% (481) 
Do not wish to respond 6.6% (140) 
Ethnic group (n=2,126) 
 
White British 81.5% (1,732) 
White other 13.0% (277) 
Black 1.7% (37) 
Asian 2.5% (54) 
Other 1.2% (26) 
Relationship status at enrolment (n=2,127)  
Single 52.0% (1,105) 
One man only 40.0% (851) 
Two or more men, no women 3.2% (68) 
One or more women 4.8% (103) 
Sexual identity (n=2,123)  
Gay or homosexual 85.5% (1,815) 
Straight, bisexual or other 14.5% (308) 
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Table 2.  Situational characteristics and associations with unprotected anal intercourse.  
*p<0.05, **p<0.01, ***p<0.001 
 
 
Variable 
Frequencies Unprotected anal intercourse 
% (n) OR (95% CI) 
Any drug use by participant  
 
No drug use 57.1% (3,833) Reference 
Yes, drug use 42.9% (2,881) 2.02*** (1.67, 2.45) 
Drug use by participant: specific  
 
Poppers 20.5% (1,370) 2.35*** (1.84, 3.00) 
Alcohol 26.5% (1,776) 0.84 (0.67, 1.05) 
Erectile dysfunction medications 7.2% (485) 3.14*** (2.12, 4.67) 
Cannabis 3.9% (262) 1.59 (0.95, 2.65) 
MDMA 1.7% (113) 1.48 (0.67, 3.26) 
Crystal methamphetamine 1.1% (72) 3.14* (1.18, 8.36) 
GHB 1.4% (94) 2.32* (1.02, 5.29) 
Ketamine 1.8% (119) 1.72 (0.80, 3.06) 
Cocaine 2.1% (141) 1.56 (0.80, 3.06) 
Any drug use by partner  
 
No drug use 64.0% (4,279) Reference 
Unclear drug use 7.9% (526) 0.68* (0.48, 0.97) 
Non-specific knowledge of drug use 3.8% (253) 1.53 (0.99, 2.36) 
Knowledge of specific drug use 24.4% (1,632) 1.61*** (1.29, 1.99) 
Drug use by partner: specific  
 
Alcohol 20.9% (1,400) 1.09 (0.87, 1.38) 
Erectile dysfunction medications 2.5% (165) 4.27*** (2.19, 8.34) 
Cannabis 3.1% (205) 1.87* (1.10, 3.18) 
MDMA 1.2% (83) 2.09 (0.88, 4.95) 
Crystal methamphetamine 0.9% (62) 2.92* (1.00, 8.46) 
GHB 1.2% (79) 3.07* (1.24, 7.64) 
Ketamine 1.4% (92) 0.98 (0.43, 2.22) 
Cocaine 1.8% (118) 1.84 (0.91, 3.70) 
Location of sex  
 
Private (residence, hotel) 87.2% (5,862) Reference 
Sex-on-premises venue 7.3% (490) 0.48*** (0.33, 0.70) 
Cruising or outdoors location 5.5% (371) 0.29*** (0.19, 0.46) 
Relationship status with partner(s)  
 
Regular and steady 32.3% (2,174) Reference 
Regular, non-steady 26.3% (1,766) 0.41*** (0.32, 0.53) 
One-off encounter 41.4% (2,784) 0.16*** (0.12, 0.21) 
HIV serodiscordance  
 
Seroconcordant 43.0% (2,882) Reference 
Unknown HIV serostatus match 50.0% (3,352) 0.17*** (0.14, 0.22) 
Serodiscordant 7.0% (467) 0.31*** (0.21, 0.46) 
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Table 3.  Multivariate models testing associations with unprotected anal intercourse.  
*p<0.05, **p<0.01, ***p<0.001 
 
 
Variable 
OR (95% CI) OR (95% CI) 
n=6,582 in 2,129 groups 
n=6,580 in 2,126 
groups 
Any drug use by participant 
 
 
No drug use Reference  
Yes, drug use 2.15*** (1.69, 2.74)  
Drug use by participant: specific   
Poppers  2.56*** (1.99, 3.30) 
Alcohol  0.85 (0.67, 1.07) 
Erectile dysfunction medications  3.20*** (2.12, 4.82) 
Cannabis  1.51 (0.89, 2.57) 
MDMA  1.35 (0.59, 3.04) 
Crystal methamphetamine  2.76* (1.00, 7.58) 
GHB  2.43* (1.05, 5.66) 
Ketamine  1.56 (0.71, 3.43) 
Cocaine  1.67 (0.83, 3.35) 
Any drug use by partner    
No drug use Reference  
Unclear drug use 1.35 (0.91, 2.01)  
Non-specific knowledge of drug use 1.63* (1.01, 2.61)  
Knowledge of specific drug use 0.99 (0.76, 1.30)  
Location of sex    
Private (residence, hotel) Reference Reference 
Sex-on-premises venue 1.00 (0.66, 1.52) 1.08 (0.72, 1.62) 
Cruising or outdoors location 0.55* (0.34, 0.90) 0.61* (0.38, 0.98) 
Relationship status with partner(s)    
Regular and steady Reference Reference 
Regular, non-steady 0.54*** (0.41, 0.71) 0.49*** (0.37, 0.65) 
One-off encounter 0.25*** (0.19, 0.34) 0.25*** (0.19, 0.33) 
HIV serodiscordance    
Seroconcordant Reference Reference 
Unknown HIV serostatus match 0.27*** (0.21, 0.35) 0.29*** (0.23, 0.37) 
Serodiscordant 0.30*** (0.20, 0.45) 0.28*** (0.18, 0.42) 
